113 related articles for article (PubMed ID: 30685089)
1. Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.
Abayasiriwardana KS; Wood MK; Prêle CM; Birnie KA; Robinson BW; Laurent GJ; McAnulty RJ; Mutsaers SE
Biochem Biophys Res Commun; 2019 Mar; 510(2):198-204. PubMed ID: 30685089
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
4. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
5. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
7. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Takayama Y; Hattori N; Hamada H; Masuda T; Omori K; Akita S; Iwamoto H; Fujitaka K; Kohno N
Cancer Res; 2016 Jun; 76(11):3285-94. PubMed ID: 27197170
[TBL] [Abstract][Full Text] [Related]
9. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
Manente AG; Pinton G; Zonca S; Cilli M; Rinaldi M; Daga A; Nilsson S; Moro L
Oncotarget; 2015 Sep; 6(28):25121-34. PubMed ID: 26208479
[TBL] [Abstract][Full Text] [Related]
10. Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor-β activity in malignant mesothelioma.
Vehviläinen P; Koli K; Myllärniemi M; Lindholm P; Soini Y; Salmenkivi K; Kinnula VL; Keski-Oja J
Hum Pathol; 2011 Feb; 42(2):269-78. PubMed ID: 21106222
[TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
Muscella A; Vetrugno C; Cossa LG; Antonaci G; De Nuccio F; De Pascali SA; Fanizzi FP; Marsigliante S
PLoS One; 2016; 11(11):e0165154. PubMed ID: 27806086
[TBL] [Abstract][Full Text] [Related]
12. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
[TBL] [Abstract][Full Text] [Related]
13. Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.
Pulito C; Mori F; Sacconi A; Casadei L; Ferraiuolo M; Valerio MC; Santoro R; Goeman F; Maidecchi A; Mattoli L; Manetti C; Di Agostino S; Muti P; Blandino G; Strano S
Oncotarget; 2015 Jul; 6(20):18134-50. PubMed ID: 26136339
[TBL] [Abstract][Full Text] [Related]
14. Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma.
D'Amato-Brito C; Cipriano D; Colin DJ; Germain S; Seimbille Y; Robert JH; Triponez F; Serre-Beinier V
Oncotarget; 2016 Mar; 7(10):11512-25. PubMed ID: 26883190
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural fluid from mesothelioma has potent biological activities.
Cheah HM; Lansley SM; Varano Della Vergiliana JF; Tan AL; Thomas R; Leong SL; Creaney J; Lee YC
Respirology; 2017 Jan; 22(1):192-199. PubMed ID: 27560254
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
[TBL] [Abstract][Full Text] [Related]
18. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
Sage EK; Kolluri KK; McNulty K; Lourenco Sda S; Kalber TL; Ordidge KL; Davies D; Gary Lee YC; Giangreco A; Janes SM
Thorax; 2014 Jul; 69(7):638-47. PubMed ID: 24567297
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
Li C; Rezov V; Joensuu E; Vartiainen V; Rönty M; Yin M; Myllärniemi M; Koli K
Sci Rep; 2018 Jul; 8(1):10070. PubMed ID: 29968778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
